Improvement in the Appearance of Periorbital Wrinkles

NCT05082766 | Unknown Phase 3

• 1 other identifier: DefenAge-2021-01
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this study is to evaluate the efficacy of DefenAge 8-in-1 BioSerum supplemented with the enhanced concentration of defensins (enhanced 8-in-1 BioSerum) in the improvement of periorbital wrinkles.

Conditions

Periorbital Wrinkles

Keywords

wrinkles; crow's feet; face wrinkles; face; cosmetic

Outcome Measures

Primary Outcomes (2)

• Clinician evaluator assessment of change using Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale

  measurements will be completed based on images captured at baseline, Day 30, Day 60, and Day 90 and assessed by a blinded evaluator using the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale where wrinkling ranges from class 1 (fine wrinkles) to class 3 (Fine to deep wrinkles, numerous lines, with or without redundant skin folds) and Elastosis ranges from 1-3 (mild) to 7-9 (severe)

  baseline, Day 30, Day 60, and Day 90

• Asses the change of Percent of improvement at different time points

  Percent improvement in periorbital wrinkles, laxity, pigmentation, erythema, texture, and radiance conducted by an evaluator

  Day 30, Day 60, and Day 90

Secondary Outcomes (4)

• Investigator-assessed Global Aesthetic Improvement Score (I-GAIS)

  Day 30, 60 and 90

• Subject Global Aesthetic Improvement Score (S-GAIS)

  Day 30, 60 and 90

• Investigator assessment of tolerability of study drug including erythema, burning/stinging, dryness, peeling (desquamation), and tenderness

  Day 30, 60 and 90.

• Patient questionnaire

  Day 30, 60 and 90.

Study Arms (1)

DefenAge 8-in-1 BioSerum supplemented with enhanced concentration of defensins

EXPERIMENTAL

Enrolled subjects will all receive enhanced DefenAge 8-in-1 BioSerum to be applied on the face including periorbital area.

Drug: enhanced DefenAge 8-in-1 BioSerum

Interventions

enhanced DefenAge 8-in-1 BioSerum DRUG

DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.

DefenAge 8-in-1 BioSerum supplemented with enhanced concentration of defensins

Eligibility Criteria

• Age: 31 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects in general good health greater than 30 years of age
• Must be willing and capable of giving consent and signing an Informed Consent Form
• Subjects with moderate to severe periorbital wrinkles (at least a grade II in wrinkles and score of 4 in elastosis on the Fitzpatrick-Goldman wrinkle scale)
• Female Subjects will be either of non-childbearing potential defined as:
• Having no uterus
• No menses for at least 12 months
• Bilateral tubal ligation Or; (WOCBP) women of childbearing potential, must have had a regular menstrual cycle prior to study entry. All systemic birth control measures must be in consistent use at least 6 months prior to study participation. WOCBP must agree to use an effective method of birth control during the course of the study, such as:
• <!-- -->
• Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device
• Intrauterine coil
• Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)
• Abstinence or same sex partner (If practicing abstinence or sexual activity with a same sex partner, must agree to use barrier method described above (c) if becomes sexually active with a non-vasectomized male partner).
• Vasectomized male partner (for at least 6 months) (must agree to use barrier method described above (c) if becomes sexually active with un-vasectomized male partner).
• Negative urine pregnancy test results at Baseline prior to study entry (if applicable)

You may not qualify if:

• History of sensitivity to any ingredient in DefenAge 8-in-1 BioSerum.
• Subjects receiving any topical cosmetic anti-wrinkle and/or skin lightening products known to affect skin aging such as products containing hydroquinone, vitamin A derivatives (retinol, tretinoin, adapalene, tazarotene), alpha/beta/poly-hydroxy acids (salicylic acid, glycolic acid etc.), vitamins C or D (includes derivatives thereof), arbutin, retinol, azelaic acid, kojic acid, licorice extracts, bearberry extracts, mequinol) on the treatment area within 14 days prior to or during the study period, other than the study product.
• Subjects using any topical imiquimod, 5-fluorouracil, or diclofenac on their face within 12 weeks prior to or during the study period
• Subjects who have had a microdermabrasion (light or medium skin peel on their face within 30 days prior to or during the study period
• Subjects receiving a chemical peel, a non-ablative laser, light, radiofrequency, or ultrasound treatment on their face must have discontinued the drug/treatment at least 3 months prior to entering the study
• Subjects receiving Dermabrasion (deep skin peel) and/or ablative laser treatments on their face, and systemic retinoids must have discontinued the drug/treatment at least 6 months prior to entering the study
• History of or the presence of any skin condition/disease that might, in the opinion of the investigator, interfere with the diagnosis or evaluation of study parameters (i.e., acne, atopic dermatitis, eczema, psoriasis, seborrheic dermatitis)
• Subjects with current actinic keratoses or any other skin cancer(s) in the treatment areas
• Subjects with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study
• Subjects with any active systemic disease that is not yet deemed medically stabilized
• Subjects with an active bacterial, fungal, or viral infection
• Subjects participating or completing participation in a clinical trial within 30 days prior to or during the study period
• A female subject who is currently breast-feeding, nursing, pregnant or planning to becoming pregnant during the study period
• Subjects not willing to comply with study dosing and complete the entire course of the study
• Subjects not willing to avoid extended periods of sun exposure for the duration of the study (including tanning beds). During the study, when excessive sun exposure is unavoidable, subjects should wear appropriate protective clothing and use the dispersed sunscreen

Sponsors & Collaborators

• Goldman, Butterwick, Fitzpatrick and Groff: lead
• Advanced Dermatology: collaborator
• MediCell Technologies, LLC: collaborator

Study Sites (1)

West Dermatology Research Center/Cosmetic Laser Dermatology

San Diego, California, 92121, United States

RECRUITING

Related Publications (1)

• Taub A, Bucay V, Keller G, Williams J, Mehregan D. Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen With Clinical, Histopathologic, Immunohistochemical, Photographic, and Ultrasound Evaluation. J Drugs Dermatol. 2018 Apr 1;17(4):426-441.

  PMID: 29601620 BACKGROUND

MeSH Terms

Conditions

Facies

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Sabrina G Fabi, MD

  Cosmetic Laser Dermatology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sherif Mikhail, MD

CONTACT

8586571004; SMikhail@CLDerm.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: will be treated with the enhanced DefenAge 8-in-1 BioSerum to their entire face

Study Record Dates

• First Submitted: September 24, 2021
• First Posted: October 19, 2021
• Study Start: October 11, 2021
• Primary Completion: October 11, 2022
• Study Completion: December 1, 2022
• Last Updated: October 28, 2021

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)